Crossref
NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?
AME Clinical Trials Review · 2024
DOI: 10.21037/actr-23-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Shuai Wang und 1 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wang, S., & Cheng, H. (2024). NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-26
Vancouver
Wang S, Cheng H. NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-26
BibTeX
@article{Wang2024,
author = {Wang, Shuai and Cheng, Haiying},
title = {NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?},
journal = {AME Clinical Trials Review},
year = {2024},
doi = {10.21037/actr-23-26}
}
EUVIMED